Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while ProShares UltraPro Short QQQ ETF trades at $39.99. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while ProShares UltraPro Short QQQ ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| GILD | SQQQ | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $97.60 |
52-Week Low | $108.22 | $36.31 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $40.511, up 4.87% over the past 24 hours. The technical outlook is neutral with mixed signals from moving averages and oscillators, while support and resistance levels are tightly clustered. As a leveraged inverse ETF designed to deliver -3x the daily return of the Nasdaq-100, it carries inherent structural risks and is unsuitable for long-term holding due to daily reset mechanics that can erode value over time.
The outlook for SQQQ remains highly speculative and tactical. It may offer short-term hedging benefits against Nasdaq-100 declines but presents severe long-term erosion risks. Investors should strictly limit exposure to sophisticated, active traders who can closely monitor market timing, as its performance is entirely dependent on short-term directional bets against the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
